NovantaNOVT
Recorded

Novanta 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration49 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning. My name is Jamie, and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta Incorporated's third quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. To ask a question, you may press star and then one on your touchtone phones. To withdraw your question, you may press star and two. Please also note, today's event is being recorded. At this time, I'd like to turn the floor over to Marcy Meditz, Corporate Finance Leader for Novanta.

Marcy MeditzCorporate Finance Leader

Please go ahead. Thank you very much.

Marcy MeditzCorporate Finance Leader

Good morning, and welcome to Novanta's third quarter 2026 earnings conference call. This is Marcy Meditz, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra, our Chief Financial Officer, Robert Buckley, and our Co-Chief Operating Officers, Chuck Ravetto and John Lesica. If you have not received a copy of our earnings press release issued last night, you may obtain it from our investor relations section of our website at www.novanta.com. Please note, this call is being webcast live and will be archived on our website shortly after the call. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued last night, and also those in our SEC filings.

Marcy MeditzCorporate Finance Leader

We may make some comments today, both in our prepared remarks and in our responses to questions, that may include forward-looking statements. These involve inherent assumptions with known and unknown risks and other factors that could cause our future results to differ materially from our current expectations. Any forward-looking statements made today represent our views only as of this time. We disclaim any obligation to update forward-looking statements in the future, even if our estimates change. You should not rely on any of these forward-looking statements as representing our views as of any time after this call. During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available as an attachment to our earnings press release.

Marcy MeditzCorporate Finance Leader

To the extent that we use non-GAAP financial measures during this call that are not reconciled to GAAP measures in the earnings press release, we will provide reconciliations promptly on the investor relations section of our website after this call. I am now pleased to introduce the Chair and Chief Executive Officer of Novanta, Matthijs Glastra.

Matthijs GlastraChair and CEO

Thank you, Marcy. Good morning, everybody, and thanks for joining our call. The third quarter was a milestone quarter for Novanta. We closed the largest acquisition in our history, Riverpoint Medical, and at the same time delivered results ahead of expectations on revenue, adjusted EBITDA, and adjusted EPS. Revenue grew 23% on a reported basis to $305 million, with organic growth of nearly 10%, our strongest organic growth in more than three years. Adjusted EBITDA grew 38% to $80 million, or 26% EBITDA margin, the highest in Novanta's history, and an expansion of 290 basis points year-over-year. Adjusted EPS grew 21% to $1.05. Customer bookings grew 29%, resulting in a book-to-bill of 1.08 and a backlog of $543 million, with core backlog up 14% year-over-year.

Matthijs GlastraChair and CEO

Year-to-date operating cash flow of $156 million is nearly three times what we generated in the same period last year. Riverpoint Medical performed in line with our expectations in the first two months as part of Novanta, with an exciting innovation pipeline ahead. Before I turn to our 2026 priorities, a word on our long-term direction and on how our proprietary competencies in high-growth markets reinforce each other. This quarter is evidence of both. Our direction has been consistent and deliberate, more medical, more recurring, and less cyclical. It drives our capital allocation, with Riverpoint the most recent example. Medical end markets are now 53% of revenue, approaching 60% on a full-year basis with Riverpoint. We win in high-growth end markets with durable secular tailwinds by solving our customers' most complex needs with proprietary platform technologies, built on competencies honed over decades.

Matthijs GlastraChair and CEO

Let me touch on three of them. First, precision motion and robotics. Servo drives, force torque sensors, and position sensors let a surgical robot position its arm with micron precision and sense force and torque, giving the surgeon a sense of feel while keeping the system safe. The same technology sits inside warehouse and humanoid robotics in advanced surgical equipment. These capabilities are one of the core drivers of our robotics and automation revenue growth, 17% in the quarter and 13% year-to-date, with sustained momentum into 2027. Second, precision fluid and flow management for minimally invasive surgery. The same precision control competency underpins our surgical insufflators and pumps, which control fluid and CO2 gas, where any loss of control puts patient safety at risk. We have leveraged this position to expand into consumables for the same endoscopic workflows.

Matthijs GlastraChair and CEO

Recurring consumables across sports medicine, minimally invasive surgery, and surgical robotics now represent roughly 25% of Novanta's revenue and have become a durable growth engine for the company. Third, laser beam steering and conditioning, shaping and controlling light with extreme precision. In ophthalmology, it supports retinal imaging and refractive eye surgery. In life sciences, it enables cellular and genetic analysis. In manufacturing, it guides the systems that builds medical implants layer by layer. In semiconductors, it sits inside the lithography systems that pattern the most advanced chips and the tools that inspect them. Our precision manufacturing business covers all these applications and grew 14% in the third quarter, with a strong innovation pipeline ramping in 2027. Running through all these three competencies is embedded software. It powers our intelligent subsystems, which now represent roughly 25% of our revenue and about 75% of our new product launches.

Matthijs GlastraChair and CEO

Embedded software lives inside the hardware, controlling it in real time and turning physical measurements into data that applications can use. Our differentiation lies in the software with proprietary control algorithms, closed-loop control, safety certification, and real-time data processing. That position makes us the source of the data. The same competencies span the fastest-growing parts of medical and advanced industrial markets, and they grow because they solve real problems: healthcare productivity through early disease detection and less invasive surgery, labor shortages through robotics in factories and warehouses, and the technologies behind the manufacturing of next-generation semiconductors, medical implants, and aerospace components. Our breadth matters commercially as well. Our largest OEM customers span multiple businesses, and we manage them as one Novanta. A design win in one business becomes the invitation into the next. Against this backdrop, we remain focused on our three priorities for 2026. First, organic growth. Our innovation engine continues to deliver, and it is what underlies our long-term algorithm of mid to high single-digit organic growth.

Matthijs GlastraChair and CEO

New product revenue grew 23% in the quarter and is up 47% year to date, lifting our vitality index to approximately 27% of sales year to date. Bookings grew 29% in the quarter, or 18% excluding Riverpoint Medical, and are up 22% year to date. Incremental design wins increased 63% in the quarter and are up 19% year to date, driven by our Novanta Growth System Commercial Excellence playbook. Three of our four business units grew organically in the quarter, led by double-digit organic growth in our Automation Enabling Technologies segment. John and Chuck will elaborate on examples of recent product launches and customers wins. Second, acquisitions. We closed Riverpoint Medical in July.

Matthijs GlastraChair and CEO

It is integrating well and performing in line with our expectation, with an exciting new product pipeline ahead. John will cover Riverpoint and our new business unit structure in more detail. Our near-term capital deployment priority is to delever, and our strong cash flow generation positions us to do that quickly to take advantage of follow-on opportunities in an active market. Our third priority for 2026 is completing our manufacturing foundation through our regional manufacturing centers of excellence for two reasons. First, greater scale, lower complexity, and lower cost. Second, full in-region, for-region capability. Our customers take ownership at our factory gates, so building closer to where they sell minimizes their tariff and logistics exposure. The strategy is making strong progress. In the second quarter, we consolidated two factories, and in the third quarter, launched the closure effect of two more.

Matthijs GlastraChair and CEO

This puts us on track for 18 factories by the end of the first quarter of 2027, down from 21 a year ago. We also implemented our new SAP MRP system without disruption at two of our lighthouse centers. Even so, our third-quarter gross margin and fourth-quarter outlook are below where we want them to be, and we own that. Much of the pressure is at our Stockport facility in the U.K., where temporary dynamics are coming together, resulting in a production slowdown in our factory for the remainder of the year. Fortunately, given the robust customer demand across Novanta, we were able to shift resources to ensure our revenue commitments are achieved regardless. We now expect production in this facility to resume in the first quarter, allowing us to expand our gross margins another 100 basis points for the full year of 2027.

Matthijs GlastraChair and CEO

John and Chuck will say more about each. The macro remains complex, and we are watching it closely, but we have strong demand, a $543 million backlog, continued new product momentum, and the strongest team Novanta has ever had. As we look to 2027, we expect a full year of Riverpoint, Stockport behind us, and our new product momentum to drive gross margin expansion and strong earnings growth. Chuck Ravetto and John Lesica will walk you through their segments, new product launches, design wins, and customer momentum behind these results. John, over to you. Thanks, Matthijs.

John LesicaCo-COO

Before I walk through the quarter, a quick word on how we will discuss the Medical Solutions segment going forward. With the addition of Riverpoint Medical, we have expanded our advanced surgery business unit into advanced surgical technologies, which brings together our integrated insufflation and smoke evacuation, arthroscopy fluid management, and medical consumables franchises with Riverpoint's fiber-based sutures and implantable materials. Medical Solutions will now be reported through two business units, advanced surgical technologies and precision medicine. Our reportable segments are not changing. Riverpoint's results are included from the date of acquisition and will be excluded from organic growth until the anniversary of the close in August of 2027. In the third quarter, revenue in the Medical Solutions segment grew 30% on a reported basis and approximately 3% organically, in line with our outlook of 2%-4% organic growth.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day